Lexeo Therapeutics Inc. (LXEO)
LXEO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1907108/000095017024028941/0000950170-24-028941-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LXEO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001907108 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
Financials · 2022
| Line | Value |
|---|---|
| Revenue | $654K |
| Net income | -$59.3M |
| Operating income | -$60.5M |
| Net margin | -9063.8% |
| Operating margin | -9252.1% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $77.3M |
| Total assets | $97.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 405.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-12 |
| Cash and burn | $92.8M cash; operating cash flow -$22.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 82,046,255 (2026-08-10); 54,001,214 a year earlier; 26,645,538 three years earlier. | Cover page 2026-08-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-10-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, New York, New York, United States | PCAOB Form AP 2026-04-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $985K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$25.9M | -$17.6M | $92.8M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$20.2M | -$21.1M | $71.8M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q4 2025 2025-12-31 | Not filed | -$21.0M | -$20.1M | $63.0M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q3 2025 2025-09-30 | Not filed | -$20.3M | -$29.5M | $41.0M | No debt tags | Needs four quarters | 10-Q 2025-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$26.1M | -$27.2M | $35.5M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | -$32.7M | -$21.7M | $28.9M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q4 2024 2024-12-31 | Not filed | -$25.9M | -$28.3M | $35.0M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$29.5M | -$17.8M | $157.0M | No debt tags | Needs four quarters | 10-Q 2025-11-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-10-29 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-08-12 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 365 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.7% |
| 1 month | +4.7% |
| 3 months | -42.1% |
| Year to date | -71.1% |
| 1 year | -68.1% |
| From 52-week high | -73.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OCGN | Ocugen Inc. | $0.7730 | -6.62% | $262.3M |
| SABS | SAB Biotherapeutics Inc. | $3.00 | +1.35% | $270.3M |
| PLX | Protalix BioTherapeutics Inc. (DE) | $3.03 | -0.66% | $255.5M |
| DTIL | Precision BioSciences Inc. | $7.28 | -3.77% | $277.6M |
| ALLO | Allogene Therapeutics Inc. | $0.8070 | -3.78% | $279.6M |
| AGEN | Agenus Inc. | $6.29 | -6.54% | $284.6M |
| EDIT | Editas Medicine Inc. | $1.87 | -13.82% | $288.6M |
| XFOR | X4 Pharmaceuticals Inc. | $2.83 | -9.29% | $289.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier